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OBJECTIVE — To investigate the effects of continuous intraperitoneal insulin infusion
(CIPII) compared with subcutaneous insulin on health-related quality of life (HRQOL) and
treatment satisfaction, and to perform a cost analysis in type 1 diabetes.
RESEARCH DESIGN AND METHODS — We used an open-label, prospective, cross-
over, randomized, 16-month study (N  24). HRQOL and patient satisfaction were assessed
with questionnaires (the 36-item short-form health survey [SF-36], the World Health Organi-
zation-Five Well-Being Index [WHO-5], and the Diabetes Treatment Satisfaction Questionnaire
[DTSQ]). Direct costs of CIPII and continuous subcutaneous insulin infusion (CSII) were
compared.
RESULTS — Questionnaire scores were higher with CIPII than with subcutaneous therapy.
Yearly direct pump- and procedure-associated costs for CIPII were estimated at €10,910 com-
pared with €4,810 for CSII.
CONCLUSIONS — Apart from improving glycemic control, CIPII improved HRQOL and
treatment satisfaction compared with subcutaneous insulin. Direct pump- and procedure-
associated costs are considerably higher for CIPII, however.
Diabetes Care 33:1169–1172, 2010
W
e recently showed that treatment
with continuous intraperitoneal
insulin infusion (CIPII) com-
pared with subcutaneous insulin results
in better glycemic control, expressed as a
0.8%-point decrease in A1C (1). The aim
of the current analysis was to assess the
effects of CIPII on health-related quality
of life (HRQOL) and treatment satisfac-
tion compared with intensiﬁed subcuta-
neous insulin therapy, and to provide up-
to-date cost calculations of direct pump-
and procedure-associated costs.
RESEARCH DESIGN AND
METHODS— The investigator-initi-
ated study had a crossover, randomized
design and was conducted in the Isala
ClinicsintheNetherlands.Thedesignhas
beendescribedindetailpreviously(1).In
brief, adult subjects with type 1 diabetes,
inadequately controlled with subcutane-
ousinsulinregimens,wererandomizedto
receive either 6 months of subcutaneous
insulin therapy followed by 6 months of
CIPII,orviceversa.Subcutaneousinsulin
was delivered with either multiple daily
injections (MDIs) or continuous subcuta-
neous insulin infusion (CSII), whatever
the patient used prior to the study.
Informed consent was obtained from
all patients. The protocol was approved
by the local ethics committee.
For HRQOL assessment, the the 36-
item short-form health survey (SF-36)
and the the World Health Organization-
Five Well-Being Index (WHO-5) ques-
tionnaires were used. The SF-36 is a
widely used, generic questionnaire with
36 items involving eight subscales and a
physical and mental component sum-
mary (PCS and MCS, respectively). Scale
scores range from 0–100, with higher
scores indicating better HRQOL (2,3).
The WHO-5 is designed to measure pos-
itive well-being and is reported to be bet-
ter in identifying depression than the
SF-36 MCS (4,5). It consists of ﬁve items
with a total score ranging from 0–100. A
score below 50 suggests poor emotional
well-being (6).
Treatment satisfaction was measured
with the Diabetes Treatment Satisfaction
Questionnaire(DTSQ).Alleightitemsare
scored on a 7-point scale. Two items as-
sess perceived frequency of hyperglyce-
mia and hypoglycemia, and six items
comprise the treatment satisfaction scale,
with higher scores indicating higher sat-
isfaction (range 0–36) (7).
Costcalculationsweredoneusingthe
Dutch manual for costing as a guideline
and using local 2007 protocols and
prices(8).Nocomparisonwithcostsfor
MDI was made. For CSII treatment,
priceswereusedforthemostfrequently
used pump and its accessories in our
hospital region: the Paradigm 512/712
(Medtronic/Minimed, Northridge, CA).
Usage of medical consumables like insu-
lin infusion sets and reservoirs was based
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were based on the Dutch national drug
compendium (June 2007 prices), in-
creasedbythepharmacists’fee(€6.10)on
the assumption of four prescriptions per
year (excluding value-added tax [VAT]).
Average daily insulin dose was based on
trial data. For CIPII treatment, actual
prices for both the intraperitoneal (IP)
pump and insulin were used. Rates for
rinse and reﬁll procedures were based on
the 2007 protocol and historical data in-
stead of trial data. Life spans of 4 and 7
yearswereassumedforsubcutaneousand
CIPII pumps, respectively (10,11). Costs
for self care and outpatient visits were
considered to be equal for both therapy
strategies and were therefore left out of
the calculations.
The general linear model was used to
test differences, taking treatment order
into account (12). Tests for possible carry
over were performed by comparing se-
quences. The McNemar test was used to
compare paired proportions. Statistical
analyses were performed with SPSS
software.
RESULTS— Baseline and outcome of
patients that completed the study (n 
23) are listed in Table 1 (a study ﬂow
chart is available in an online appendix
at http://care.diabetesjournals.org/cgi/
content/full/dc09-1758/DC1). Scores on
most subscales of the SF-36 improved
with CIPII compared with baseline. After
one study period, all scores were higher
with CIPII, although only statistically sig-
niﬁcantfortheDTSQandWHO-5scores.
There were no signiﬁcant differences
between sequences (no carry over ef-
fects). When end point scores for CIPII
and subcutaneous treatment were com-
pared, the scores on all subscales were
signiﬁcantly higher with CIPII, with the
exception of “social functioning” and
“bodily pain.”
With CIPII treatment, the number of
patients scoring below 50 was half of that
with subcutaneous treatment (6 vs. 13;
P  0.02). Furthermore, with CIPII, sub-
jects perceived signiﬁcantly less hypogly-
cemic and hyperglycemic events.
Costs are stated in detail in the online
appendix. Direct pump- and procedure-
associated costs for treatment with CIPII
wereestimatedat€10,910peryearversus
€4,810 for CSII. High costs of the IP
pump(€20,000atthetimeofthestudy)is
largely responsible for the difference.
CONCLUSIONS — Treatment with
CIPII improved HRQOL and treatment
satisfaction in patients with type 1 diabe-
tes who failed to reach satisfactory meta-
bolic control with MDI and CSII, albeit
against currently high costs.
Improvement of vitality and mental
healthontheSF-36andadeclineofprob-
lems in work and daily activities due to
emotional problems indicate that CIPII,
apart from physical improvement, im-
proves mental components of health sta-
tus as well, as conﬁrmed by the results of
theWHO-5questionnaire.Itisreassuring
to ﬁnd that, together with the beneﬁcial
effects of CIPII on HRQOL, CIPII treat-
ment satisfaction is high and increased
compared with subcutaneous treatment.
Initiation of CIPII requires hospital ad-
mission and a surgical procedure to in-
sert the pump, and could therefore be
expected to have negative effects com-
pared with treatment modalities not
needing surgery. The improvement in
glycemic control with less perceived
complaints of hypo- and hyperglycemia
probably compensates for this potential
negative effect.
Annual costs of CIPII are about
€6,000 higher than the annual costs of
CSIIatthemoment,mainlybecauseofthe
high price of the implantable pump and
the insulin used in IP pumps. A formal
cost-effectiveness analysis was beyond
the scope of this study.
Nowadays many patients are able to
achieve target levels with MDI or CSII.
Still, a considerable proportion of type 1
diabetic patients are still not able to reach
adequatecontrolandsatisfactoryHRQOL
despite all efforts. CIPII will then be a vi-
ableoption,becauseitmayimproveA1C,
HRQOL, and treatment satisfaction in se-
lected patients.
A limitation of this study is that, be-
causeoftheconsiderableincreaseincosts
and scarcity of supplies, we did not enroll
more patients. This might be the reason
we were not able to show signiﬁcant im-
provements after one study period. Al-
thoughtheinteractionbetweentreatment
and period was not signiﬁcant, we cannot
completely rule out the existence of psy-
chological carry over.
Based on our results, we conclude
that CIPII has clear beneﬁcial effects on
HRQOL and satisfaction with treatment.
CIPIIshouldbeconsideredasatreatment
option, at least when satisfactory results
of treatment are not reached with subcu-
taneous intensive insulin treatment
regimens.
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